American Century Companies Inc. Raises Stock Position in Illumina, Inc. (NASDAQ:ILMN)

American Century Companies Inc. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 226,852 shares of the life sciences company’s stock after acquiring an additional 23,338 shares during the period. American Century Companies Inc. owned approximately 0.14% of Illumina worth $30,314,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ILMN. Versant Capital Management Inc raised its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new position in Illumina during the fourth quarter worth about $32,000. Assetmark Inc. increased its stake in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina in the 4th quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina during the 4th quarter valued at about $48,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Illumina stock opened at $80.00 on Friday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market cap of $12.67 billion, a P/E ratio of -10.42, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 1-year low of $79.30 and a 1-year high of $156.66. The firm has a 50-day moving average of $102.80 and a 200-day moving average of $126.79.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on ILMN. Barclays restated an “underweight” rating on shares of Illumina in a research report on Tuesday, March 11th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Canaccord Genuity Group cut their target price on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. Robert W. Baird dropped their price target on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Finally, Guggenheim reduced their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.